Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 692-701

  Suzuki, Masayuki ^a   Honda, Kiyofumi ^a   Fukazawa, Masanori ^a   Ozawa, Kazuharu ^a   Hagita, Hitoshi ^b   Kawai, Takahiro ^a   Takeda, Minako ^a   Yata, Tatsuo ^b   Kawai, Mio ^b   Fukuzawa, Taku ^a   Kobayashi, Takamitsu ^a   Sato, Tsutomu ^a   Kawabe, Yoshiki ^a   Ikeda, Sachiya ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GLUCOSIDASE; GLYCOGEN; GLYCOSYLATED HEMOGLOBIN; INSULIN; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; TOFOGLIFLOZIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME MECHANISM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GLYCOGEN SYNTHESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; KIDNEY; MALE; MICE; MICE, INBRED STRAINS; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84861536065     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.191593     Document Type: Article

References (37)

1. Anand S, Muthusamy VS, Sujatha S, Sangeetha KN, Bharathi Raja R, Sudhagar S, Poornima Devi N, and Lakshmi BS (2010) Aloe emodin glycosides stimulates glucose transport and glycogen storage through PI3K dependent mechanism in L6 myotubes and inhibits adipocyte differentiation in 3T3L1 adipocytes. FEBS Lett 584:3170-3178.
2. Andersen B, Rassov A, Westergaard N, and Lundgren K (1999) Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-dideoxy-1,4-imino-D-arabinitol. Biochem J 342:545-550. (Pubitemid 29452639)
3. Beck FX, Burger-Kentischer A, and Müller E (1998) Cellular response to osmotic stress in the renal medulla. Pflugers Arch 436:814-827. (Pubitemid 28496726)
4. +/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics 25:507-513.
5. Bosch RR, Pouwels MJ, Span PN, Olthaar AJ, Tack CJ, Hermus AR, and Sweep CG (2004) Hexosamines are unlikely to function as a nutrient-sensor in 3T3-L1 adipocytes: a comparison of UDP-hexosamine levels after increased glucose flux and glucosamine treatment. Endocrine 23:17-24. (Pubitemid 38621635)
6. Brady RO (2006) Enzyme replacement for lysosomal diseases. Annu Rev Med 57: 283-296.
7. Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, Volk C, Wright EM, and Koepsell H (2003) A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci USA 100:11753-11758. (Pubitemid 37206007)
8. Grempler R, Augustin R, Froehner S, Hildebrandt T, Simon E, Mark M, and Eickelmann P (2012a) Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett 586:248-253.
9. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, and Eickelmann P (2012b) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83-90.
10. Hösli P (1977) Quantitative assays of enzyme activity in single cells: early prenatal diagnosis of genetic disorders. Clin Chem 23:1476-1484.
11. Iwakura H, Hosoda K, Son C, Fujikura J, Tomita T, Noguchi M, Ariyasu H, Takaya K, Masuzaki H, Ogawa Y, et al. (2005) Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice. J Biol Chem 280:15247-15256. (Pubitemid 40562881)
12. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, and Rossetti L (1991) Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulinresistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 87:561-570.
13. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, Arai M, Kawakita Y, Fukasawa Y, Iida I, Hagima N, Takeuchi H, Chino Y, et al. (2010) (1S)-1,5-Anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53:3247-3261.
14. Kanai Y, Lee WS, You G, Brown D, and Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397-404.
15. Kitamura H, Yamauchi A, Sugiura T, Matsuoka Y, Horio M, Tohyama M, Shimada S, Imai E, and Hori M (1998) Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int 53:146-153. (Pubitemid 28066914)
16. Kleta R, Stuart C, Gill FA, and Gahl WA (2004) Renal glucosuria due to SGLT2 mutations. Mol Genet Metab 82:56-58. (Pubitemid 38521129)
17. Koivisto UM, Martinez-Valdez H, Bilan PJ, Burdett E, Ramlal T, and Klip A (1991) Differential regulation of the GLUT-1 and GLUT-4 glucose transport systems by glucose and insulin in L6 muscle cells in culture. J Biol Chem 266:2615-2621. (Pubitemid 21909107)
18. Magen D, Sprecher E, Zelikovic I, and Skorecki K (2005) A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 67:34-41. (Pubitemid 40019223)
19. Martín MG, Turk E, Lostao MP, Kerner C, and Wright EM (1996) Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucosegalactose malabsorption. Nat Genet 12:216-220. (Pubitemid 26051306)
20. Mascitti V, Maurer TS, Robinson RP, Bian J, Boustany-Kari CM, Brandt T, Collman BM, Kalgutkar AS, Klenotic MK, Leininger MT, et al. (2011) Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem 54:2952-2960.
21. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, et al. (2008) Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145-1149. (Pubitemid 351480378)
22. Michalski JC and Klein A (1999) Glycoprotein lysosomal storage disorders: alphaand beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency. Biochim Biophys Acta 1455:69-84.
23. Musso G, Gambino R, Cassader M, and Pagano G (2011) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med doi: 10.3109/07853890.2011.560181.
24. Nishioka T, Kawabata J, and Aoyama Y (1998) Baicalein, an alpha-glucosidase inhibitor from Scutellaria baicalensis. J Nat Prod 61:1413-1415. (Pubitemid 28555113)
25. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, Yamamoto Y, Ueta K, Kimata H, Nakayama K, et al. (2010) Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53:6355-6360.
26. Poitout V and Robertson RP (2008) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29:351-366. (Pubitemid 351679704)
27. Roll P, Massacrier A, Pereira S, Robaglia-Schlupp A, Cau P, and Szepetowski P (2002) New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families. Gene 285:141-148. (Pubitemid 34246329)
28. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, et al. (2003) Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873-2882. (Pubitemid 37305650)
29. Sato T, Kobayashi T, Nishimoto M, Taka N, Ohtake Y, Takano K, Yamamoto K, Ohmori M, Yamaguchi M, Takami K, et al. (2010) Discovery of O-spiroketal C-arylglucosides as novel and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Scientific Abstracts for the 240th National ACS Meeting and Exposition; 2010 Aug 22-26; Boston, MA. pp MEDI-202. American Chemical Society, Washington, DC.
30. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, et al. (2012) Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385:423-436.
31. +-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 76:1039-1050.
32. Upton R, Widdowson PS, Ishii S, Tanaka H, and Williams G (1998) Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker diabetic fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br J Pharmacol 125:1708-1714. (Pubitemid 29000817)
33. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, and Van Weel C (2005) Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 18:CD003639.
34. Wisselaar HA, van Dongen JM, and Reuser AJ (1989) Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alphaglucosidases in human fibroblasts and HepG2 cells. Clin Chim Acta 182:41-52. (Pubitemid 19152778)
35. World Health Organization (2011) Fact sheet No. 312 "Diabetes." World Health Organization, Geneva, Switzerland.
36. Wright EM, Martín GM, and Turk E (2001) Familial glucose-galactose malabsorption and hereditary renal glycosuria, in Metabolic Basis of Inherited Disease, 8th ed (Scriver CR, Beaudet AL, Sly WS, and Valle D eds), vol III, pp 4891-4908, McGraw Hill, New York.
37. Wright EM, Loo DD, and Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733-794.